BiCNU

BiCNU

carmustine

Manufacturer:

Emcure

Distributor:

Hind Wing
Concise Prescribing Info
Contents
Carmustine
Indications/Uses
Palliative therapy as a single agent or in established combination therapy w/ other approved chemotherapeutic agents in: Brain tumors- glioblastoma, brainstem glioma, medulloblastoma, astrocytoma, ependymoma, metastatic brain tumors; multiple myeloma in combination w/ prednisone; Hodgkin's disease as secondary therapy in combination w/ other approved drugs in patients who relapse while being treated w/ primary therapy, or who fail to respond to primary therapy; non-Hodgkin's lymphomas as secondary therapy in combination w/ other approved drugs for patients who relapse while being treated w/ primary therapy, or who fail to respond to primary therapy.
Dosage/Direction for Use
As a single agent in previously untreated patients: 150-200 mg/m2 IV every 6 wk, given as a single dose or divided into daily inj eg, 75-100 mg/m2 on 2 successive days.
Contraindications
Special Precautions
Pulmonary toxicity. Bone marrow toxicity. Development of secondary malignancies w/ long-term use. Inj site reactions. Carcinogenic potential. Should not be given more frequently than every 6 wk. Monitor blood counts wkly for at least 6 wk after a dose. Periodically monitor liver & renal function tests. Perform baseline pulmonary function studies w/ frequent pulmonary function tests during treatment. Accidental contact of reconstituted BiCNU w/ the skin has caused transient hyperpigmentation of the affected area. May cause fetal harm when administered to pregnant woman. Discontinue breastfeeding while on treatment. Ped patients. Elderly.
Adverse Reactions
Pulmonary infiltrates &/or fibrosis; myelosuppression; nausea, vomiting; increased transaminase, alkaline phosphatase, bilirubin levels; renal abnormalities. Neuroretinitis, chest pain, headache, allergic reaction, hypotension, tachycardia.
Drug Interactions
Increased myelotoxicity w/ cimetidine.
MIMS Class
Cytotoxic Chemotherapy
ATC Classification
L01AD01 - carmustine ; Belongs to the class of alkylating agents, nitrosoureas. Used in the treatment of cancer.
Presentation/Packing
Form
BiCNU inj 100 mg
Packing/Price
1's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Sign up for free
Already a member? Sign in